Track Ind-Swift Laboratories Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: -8.37 %
Low
325.0
High
371.6
1 Month returns: -6.17 %
Low
316.0
High
426.6
1 Year returns: 245.69 %
Low
87.0
High
426.6
3 Year CAGR: 51.75 %
Low
67.2
High
426.6
5 Year CAGR: 34.91 %
Low
52.7
High
426.6
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Ind-Swift Laboratories Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Ind-Swift Laboratories Ltd. Shareholding Pattern
Quarterly breakdown of Ind-Swift Laboratories Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Ind-Swift Laboratories Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Ind-Swift Laboratories Ltd.?
The current share price of Ind-Swift Laboratories Ltd. is ₹ 330.20 as of 19 Nov 2026.
What is the market capitalisation of Ind-Swift Laboratories Ltd.?
The market capitalisation of Ind-Swift Laboratories Ltd. stands at ₹ 2,871.49 Cr.
What is the PE ratio of Ind-Swift Laboratories Ltd.?
The Price-to-Earnings (PE) ratio of Ind-Swift Laboratories Ltd. is 33.70 as of the latest trailing twelve months data.
What is the ROE and ROCE of Ind-Swift Laboratories Ltd.?
Ind-Swift Laboratories Ltd. has a Return on Equity (ROE) of 6.12% and a Return on Capital Employed (ROCE) of 2.08% as per the latest financial reports.
What is the 52-week high and low of Ind-Swift Laboratories Ltd.?
The 52-week high of Ind-Swift Laboratories Ltd. is - and the 52-week low is -.
What is the dividend yield of Ind-Swift Laboratories Ltd.?
The dividend yield of Ind-Swift Laboratories Ltd. is 0.00% based on the current market price.
What is the FII and DII holding in Ind-Swift Laboratories Ltd.?
Foreign Institutional Investors (FII) hold 10.78%, Domestic Institutional Investors (DII) hold 0.00% and retail/public investors hold 39.85% of Ind-Swift Laboratories Ltd. shares.
What sector does Ind-Swift Laboratories Ltd. belong to?
Ind-Swift Laboratories Ltd. operates in the Healthcare sector.
What is the beta of Ind-Swift Laboratories Ltd.?
The beta of Ind-Swift Laboratories Ltd. is 0.58, indicating its price volatility relative to the broader market. Over the past 1 year, Ind-Swift Laboratories Ltd. has delivered an absolute return of 220.21%.
What is the RSI of Ind-Swift Laboratories Ltd.?
The 14-day Relative Strength Index (RSI) of Ind-Swift Laboratories Ltd. is 42.13, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.
Stock Analysis
Fundamental analysis overview of Ind-Swift Laboratories Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Strong price momentum
Price Momentum score of 92.6 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term
What is Price Momentum score?
92.6 / 100
Negative
Expensive and at a premium to industry median P/E
PE TTM of 33.7 indicates that the stock is expensive on a standalone basis and is at a 11.07% premium to industry median P/E
What is P/E Ratio?
Median: 30.34
Value 33.7
-33.321235.46
Low and declining ROE
The company reported low ROE of 6.12% for 12-month ended 30 Sep 2026 and ROE declined by -1680 bps from 1 year ago
What is ROE (FY)?
Low revenue growth and lower than median growth of industry
The company delivered moderate revenue growth of -5.63% for 12-month ended 30 Sep 2026 and the growth was 19.16 percentage points lower than median growth of industry
What is Sales growth (1Y)?
Median: 13.53
Value -5.63
-99.854019.76
Low EPS growth and lower than median growth of industry
The company delivered moderate EPS growth of -73.73% for 12-month ended 30 Sep 2026 and the growth was 87.39 percentage points lower than median growth of industry
What is EPS growth (1Y)?
Reasonable Debt to Equity, but increasing
The company has reasonable Debt to Equity of 1.04 as on 30 Sep 2026 but Debt to Equity increased by 1.02 in the last 1 year
What is Debt to Equity?
Low dividend yield
The company has a low dividend yield of 0.0%
What is Dividend yield?
Neutral
Low operating margin but improving trend
The company reported low operating margin of 2.26% for 12-month ended 30 Sep 2026 but operating margin improved by 596 bps from 1 year ago
What is Operating profit margin?
Company's earnings are of moderate quality
Earnings quality score of 32.7 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
32.7 / 100
Stock in ASM list
The stock has been places in Additional Surveillance Measure (ASM) list (LTASM - I (13)).
Net Revenue FY
Profit After Tax FY
ROE FY
EBITDA FY
Mar 2020
Jun 2020
Sep 2020
Dec 2020
Mar 2021
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Promoter
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.01
42.00
42.00
40.94
40.94
39.50
39.50
42.99
42.93
42.93
Indian Promoter
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.00
42.01
42.00
42.00
40.94
40.94
39.50
39.50
42.99
42.93
42.93
Foreign Promoter
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Institutions
19.78
19.49
19.54
19.54
19.66
19.55
19.50
19.72
19.55
19.49
19.49
19.53
19.49
19.57
19.66
19.04
8.28
2.20
1.59
1.40
3.98
5.18
15.48
15.01
13.88
10.87
10.98
Mutual Funds / UTI
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
FI/Bank/Insurance
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Govt
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
FII
0.28
0.00
0.04
0.04
0.17
0.05
0.01
0.22
0.06
0.00
0.00
0.04
0.00
0.08
0.17
0.31
0.26
1.27
0.65
0.46
3.07
4.27
14.80
14.33
13.88
10.70
10.78
Other Institutions
19.49
19.49
19.49
19.49
19.49
19.49
19.49
19.49
19.49
19.49
19.49
19.49
19.49
19.49
19.49
18.73
8.03
0.94
0.94
0.94
0.91
0.91
0.68
0.68
0.00
0.17
0.20
Non-Institution
38.23
38.50
38.47
38.47
38.34
38.46
38.50
38.29
38.44
38.50
38.50
38.47
38.50
38.43
38.33
38.95
49.72
55.80
56.41
56.60
55.07
53.87
45.02
45.50
43.12
46.20
46.09
Bodies Corporate
9.32
9.32
8.99
8.56
8.01
7.69
7.74
7.35
7.18
7.11
7.12
7.11
7.12
7.23
7.87
7.87
16.86
16.49
16.50
15.13
13.99
7.10
5.64
5.73
5.69
7.12
6.24
Others (incl. Retail)
No. of shareholders
28.91
14,371
29.18
15,000
29.48
14,764
29.91
14,640
30.33
15,674
30.77
21,262
30.76
25,015
30.94
24,330
31.26
25,146
31.39
24,720
31.38
24,040
31.36
24,271
31.38
23,221
31.20
22,765
30.46
25,186
31.08
24,437
32.86
22,271
39.31
25,264
39.91
28,681
41.47
28,554
41.08
27,932
46.77
28,506
39.38
43,511
39.77
41,865
37.43
38,975
39.08
40,588
39.85
42,379
Name
Month
Transaction
Holding % pre transaction
Average price
Qty.
Transaction value
Essix Biosciences Limited
Promoter
March-2026
Conversion of security (Acquisition)
2nd Mar 2026
34.04 %
₹ 0.00
51.00 lac
₹ 0.00
Essix Biosciences Limited
Promoter
July-2025
Conversion of security (Acquisition)
5th Jul 2025
36.83 %
₹ 121.00
11.00 lac
₹ 13.31 cr
GAGAN AGGARWAL
KMP
September-2024
Market Sale (Disposal)
12th Sep 2024
0.29 %
₹ 141.41
30.00 k
₹ 42.42 lac
ESSIX BIOSCIENCES LIMITED
Promoter
April-2024
Inter-se Transfer (Acquisition)
3rd Apr 2024
21.71 %
₹ 101.00
95.00 lac
₹ 95.95 cr
IND SWIFT LIMITED
Promoter
April-2024
Inter-se Transfer (Disposal)
3rd Apr 2024
16.08 %
₹ 101.00
95.00 lac
₹ 95.95 cr
ATUL KUMAR CHAUBEY
Designated Person
June-2023
Market Sale (Disposal)
30th Jun 2023
0.06 %
₹ 86.23
38.50 k
₹ 33.20 lac
RAJESH NAG
Designated Person
June-2023
Market Sale (Disposal)
19th Jun 2023
0.04 %
₹ 72.81
25.80 k
₹ 18.78 lac
SATISH SHARMA
Designated Person
June-2023
Market Sale (Disposal)
7th Jun 2023
0.02 %
₹ 72.15
14.80 k
₹ 10.68 lac
Lovekesh Mahajan
Employee
June-2023
Market Sale (Disposal)
5th Jun 2023
0.13 %
₹ 72.00
15.00 k
₹ 10.80 lac
Lovekesh Mahajan
Employee
June-2023
Market Sale (Disposal)
3rd Jun 2023
0.17 %
₹ 71.41
21.94 k
₹ 15.67 lac
Corporate Actions
History of Ind-Swift Laboratories Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.
Dividend₹ 1/share
Record date: 21st Sep 2011Ex-date: 20th Sep 2011
Announced on: 25th May 2011
Dividend₹ 1/share
Record date: 18th Sep 2010Ex-date: 16th Sep 2010
Announced on: 29th May 2010
Dividend₹ 1/share
Record date: 19th Sep 2009Ex-date: 17th Sep 2009
Announced on: 29th Jun 2009
Dividend₹ 1/share
Record date: 22nd Sep 2008Ex-date: 18th Sep 2008
Announced on: 19th Jun 2008
Dividend₹ 1/share
Record date: 25th Sep 2007Ex-date: 21st Sep 2007
Announced on: 30th Jul 2007
Company Profile
Overview of Ind-Swift Laboratories Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Compan...
Key personnel
Mr. Gagan Aggarwal
Chief Financial Officer
Mr. Varun Chhabra
Senior Vice President - Marketing
Mr. Ashok Prasad
Senior Vice President - R&D
Shri. Pardeep Verma
Compliance Officer, Vice President - Corporate Affairs, Company Secretary
Mr. Atul Chaubey
Group HR Head
Vijay Singla
Deputy Chief Operating Officer
Shri. Navrattan R. MunjalD
Executive Chairman of the Board, Managing Director